bioRxivCancer BiologyPreprint
FOXO1 inhibition and FADD knockdown have opposing effects on anticancer drug-induced cytotoxicity and p21 expression in osteosarcoma
Danielle Walker, Antanay Hall, Alexis Bonwell, Nancy Beatriz GordoniD, Danielle Robinson, Mario G. Hollomon
Abstract
Forkhead box class O1 (FOXO1) and fas-associated death domain (FADD) regulate cell death pathways and homeostatic processes such as cell cycle progression and apoptosis. FADD phosphorylation promotes nuclear localization of FOXO1 and FOXO1 regulates FADD expression. Therefore, it is plausible that FOXO1 and FADD have synergistic or antagonistic effects on cell cycle regulation and the response to anticancer drug treatment in cancer cells. In the present study we report that AS1842856-mediated inhibition of FOXO1 reverses anticancer drug-induced cytotoxicity while FADD knockdown increases anticancer drug-induced cytotoxicity in osteosarcoma (OS). Reversed anticancer drug-induced cytotoxicity was accompanied with G2/M cell cycle arrest and increased expression of p21. The anti-cancer function of FOXO1 was further supported by the observation that OS cells that express higher basal levels of FOXO1 had increased sensitivity to camptothecin-induced cytotoxicity. FADD knockdown reversed FOXO1 inhibition-induced increase in p21 expression. The results presented in this study indicate that FOXO1 has a tumor suppressor function while FADD has a tumor promoting function in OS following anticancer drug treatment. The experimental approach used in this investigation also indicates that FADD antagonists the effect of FOXO1 on p21 expression in OS.
- organism: human
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DEPDC1/ EEF1A1 complex promotes the progression of human osteosarcoma via downregulation of FOXO3a
- Mechano-inhibition of Endocytosis Sensitizes Cancer Cells to Fas-induced Apoptosis
M. Kural, U. Djakbarova, … C. Kural·bioRxiv·Jun 14, 2022
- Therapeutic modulation of ROCK overcomes metabolic adaptation of cancer cells to OXPHOS inhibition and drives synergistic anti-tumor activity
Nicholas Blazanin, Xiaobing Liang, … Yonathan Lissanu·bioRxiv·Sep 16, 2024
- The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in colon cancer cells
V. Slaninova, L. Heron-Milhavet, … A. Djiane·bioRxiv·Mar 17, 2023
- Synergistic Antitumor Activity of SUMO1 degrader and Oxaliplatin through G6PD Inhibition in Colorectal Cancer
Sung Han Jung, Rakhim Roy, … Anita C. Bellail·bioRxiv·Apr 8, 2025
- Downregulation of acetyl-CoA carboxylase suppresses the malignant progression of oral cancer
Zhen Xu, Guodong Jia·Biotechnic & HistochemistryPeer-reviewed·Sep 12, 2025